←
Bioprocess Online15,026 posts
Bioprocess Online avatar

Bioprocess Online

@BioProcessOL

Providing biopharmaceutical professionals with timely insights from field experts, including the latest best practices in upstream and downstream processes.

◷ Joined June 2009▧ 1,605 Photos and videos
Bioprocess Online avatar
Bioprocess Online@BioProcessOL·12h

When performance goes sideways, automated bioprocesses need a manual fallback state, according to Gaurav Walia at @PQEGroup, who writes about narrowing the gap between advisory and closed loop models. bioprocessonline.com/doc/clo…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 16

So many acronyms, so many different manufacturing problems. Robert Dream sorts the ADCs from the AOCs from the ATMPs, and explains why no single development strategy covers them. bioprocessonline.com/doc/com…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 9

Biopharmaceutical packaging has some non-negotiable attributes, and they can limit sustainability efforts. @josesaizmonzon says reducing packaging footprint boils down to two objectives: preserving the goods inside and maintaining compliance. bioprocessonline.com/doc/wan…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 5

Flawed individual AI outputs might seem plausible until you trend them. The latest Annex 22 draft aims to rein in the gap between single items and the whole process. Sachin Bhandari at TrustBridge Compliance breaks it down. bioprocessonline.com/doc/wha…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 4

Big bang: a complex system change or upgrade that happens all at once with no option to rollback. @Roche leaders explained one such cutover involving three integrated systems at a fill/finish site in Kaiseraugst. bioprocessonline.com/doc/how…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 4

Clonal cell line selection can take weeks (or longer), and that's why people like Susan Sharfstein, Ph.D., are devising ways to accelerate the process. Watch the full interview with Sharfstein at Bioprocess Online or wherever you get your podcasts: bioprocessonline.com/doc/str…

2:01
Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Nov 3

Distance makes a quantifiable difference that POC manufacturing can solve, writes Boro Dropulić. For people in poverty living 50 miles-plus from academic medical centers, "each additional 10 miles lowers their likelihood of getting CAR-T therapy by 6%."

Post attachment
Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Oct 29

FDA's on-again-off-again policy for CRL release indicates "a general lack of clarity about what the FDA’s campaign for 'radical transparency' should look like in practice," writes @joshcmorrison of @1daysooner. bioprocessonline.com/doc/an-…

Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Oct 28

Futuristic vision or imminent reality? On Nov. 17, panelists from Sanofi, Octapharma, and PQE Group will discuss what it takes to move from automation to predictive control — and how soon we might see truly autonomous manufacturing. Register for free: event.on24.com/wcc/r/5512381…

Post attachment
Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Oct 27

War in the Gulf, tariffs up to 100%, and attacks on clinical trial data have a direct effect on most analytical disciplines but to varying degrees. Here's how one analyst describes the impact of global disruption on analytics.

Post attachment
Bioprocess Online avatar
Bioprocess Online@BioProcessOL·Oct 26

The higher the DAR, the better, right? Not so fast. When developing ADCs, high DAR doesn't always mean a better drug. As Robert Dream explains, more payload can lead to problems like hydrophobicity and aggregation. bioprocessonline.com/doc/eng…